The  	The  	 DT	O
contribution  	contribution  	 NN	B-NP
of  	of  	 IN	I-NP
non-human  	non-human  	 JJ	I-NP
primate  	primate  	 JJ	I-NP
models  	models  	 NNS	I-NP
to  	to  	 TO	O
the  	the  	 DT	O
development  	development  	 NN	O
of  	of  	 IN	O
human  	human  	 JJ	O
vaccines  	vaccines  	 NNS	O
The  	The  	 DT	O
non-human  	non-human  	 JJ	B-NP
primates  	primates  	 NNS	I-NP
( 	( 	 -LRB-	O
NHPs 	NHPs 	 NNP	B-NP
)  	)  	 -RRB-	O
model  	model  	 NN	O
in  	in  	 IN	O
biomedical  	biomedical  	 JJ	B-NP
research  	research  	 NN	I-NP
has  	has  	 VBZ	O
contributed  	contributed  	 VBN	O
to  	to  	 TO	O
the  	the  	 DT	O
study  	study  	 NN	O
of  	of  	 IN	O
human  	human  	 JJ	O
infectious 	infectious 	 NN	B-NP
,  	,  	 ,	O
autoimmune 	autoimmune 	 NN	B-NP
,  	,  	 ,	O
oncogenic 	oncogenic 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
neurological  	neurological  	 JJ	B-NP
diseases 	diseases 	 NNS	I-NP
.  	.  	 .	O
This  	This  	 DT	O
review  	review  	 NN	O
focuses  	focuses  	 VBZ	O
on  	on  	 IN	O
the  	the  	 DT	O
importance  	importance  	 NN	O
of  	of  	 IN	O
NHP  	NHP  	 NNP	B-NP
models  	models  	 NNS	O
in  	in  	 IN	O
vaccine  	vaccine  	 NN	B-NP
development  	development  	 NN	I-NP
for  	for  	 IN	O
tuberculosis 	tuberculosis 	 NN	O
,  	,  	 ,	O
pertussis 	pertussis 	 NN	B-NP
,  	,  	 ,	O
Dengue 	Dengue 	 NNP	B-NP
,  	,  	 ,	O
group  	group  	 NN	O
A  	A  	 DT	O
streptococcus  	streptococcus  	 NN	O
( 	( 	 -LRB-	O
Streptococcus  	Streptococcus  	 UH	B-NP
pyogenes 	pyogenes 	 UH	I-NP
)  	)  	 -RRB-	O
infection 	infection 	 NN	B-NP
,  	,  	 ,	O
HIV  	HIV  	 NNP	B-NP
infection 	infection 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
certain  	certain  	 JJ	O
diseases  	diseases  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
elderly  	elderly  	 JJ	O
( 	( 	 -LRB-	O
influenza 	influenza 	 UH	B-NP
,  	,  	 ,	O
for  	for  	 IN	O
example 	example 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
From  	From  	 IN	O
understanding  	understanding  	 VBG	B-NP
disease  	disease  	 NN	I-NP
pathogenesis  	pathogenesis  	 NNS	I-NP
and  	and  	 CC	O
mechanisms  	mechanisms  	 NNS	O
of  	of  	 IN	O
protection 	protection 	 NN	O
,  	,  	 ,	O
to  	to  	 TO	O
assessing  	assessing  	 VBG	B-NP
vaccine  	vaccine  	 NN	I-NP
safety  	safety  	 NN	I-NP
and  	and  	 CC	O
efficacy 	efficacy 	 NN	O
,  	,  	 ,	O
we  	we  	 PRP	O
discuss  	discuss  	 VB	O
selected  	selected  	 VBN	B-NP
cases  	cases  	 NNS	I-NP
where  	where  	 WRB	O
the  	the  	 DT	O
importance  	importance  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
NHP  	NHP  	 NNP	B-NP
models  	models  	 NNS	O
is  	is  	 VBZ	O
highlighted 	highlighted 	 VBN	O
.  	.  	 .	O
